

Giovanni B Vigna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1744479/publications.pdf>

Version: 2024-02-01

56
papers

2,071
citations

257357

24
h-index

233338

45
g-index

60
all docs

60
docs citations

60
times ranked

2543
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. <i>Lancet</i> , The, 2013, 381, 40-46.	6.3	624
2	Role of Anti-Oxidants in Atherosclerosis: Epidemiological and Clinical Update. <i>Current Pharmaceutical Design</i> , 2005, 11, 2017-2032.	0.9	103
3	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 136, 332-335.	1.6	103
4	Effect of a standardized grape seed extract on low-density lipoprotein susceptibility to oxidation in heavy smokers. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1250-1257.	1.5	95
5	Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 805-809.	1.1	80
6	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
7	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. <i>Advances in Therapy</i> , 2017, 34, 1200-1210.	1.3	56
8	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017, 29, 11-16.	1.2	53
9	Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD). <i>BBA Clinical</i> , 2016, 5, 25-28.	4.1	50
10	Severe hypercholesterolaemia: unusual inheritance in an Italian pedigree. <i>European Journal of Clinical Investigation</i> , 1995, 25, 322-331.	1.7	48
11	Lipoprotein(a), Inflammation, and Peripheral Arterial Disease in a Community-Based Sample of Older Men and Women (the INCHIANTI Study). <i>American Journal of Cardiology</i> , 2010, 105, 1825-1830.	0.7	48
12	Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. <i>Acta Diabetologica</i> , 2013, 50, 241-249.	1.2	48
13	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018, 277, 413-418.	0.4	48
14	Plasma lipoprotein composition, apolipoprotein(a) concentration and isoforms in β^2 -thalassemia. <i>Atherosclerosis</i> , 1997, 131, 127-133.	0.4	45
15	The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-hoc analysis of a Phase 3, single-arm, open-label trial. <i>Atherosclerosis</i> , 2015, 240, 408-414.	0.4	36
16	Analbuminaemia: a natural model of metabolic compensatory systems. <i>Journal of Inherited Metabolic Disease</i> , 1987, 10, 317-329.	1.7	35
17	Lipids and other risk factors selected by discriminant analysis in symptomatic patients with supra-aortic and peripheral atherosclerosis.. <i>Circulation</i> , 1992, 85, 2205-2211.	1.6	33
18	Bilateral strio-pallido-dentate calcinosis (Fahr's disease): report of seven cases and revision of literature. <i>BMC Neurology</i> , 2016, 16, 165.	0.8	33

#	ARTICLE	IF	CITATIONS
19	Effect of age on the response of blood lipids, body composition, and aerobic power to physical conditioning and deconditioning. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 161-165.	1.5	32
20	Flow-mediated dilation, carotid wall thickness and HDL function in subjects with hyperalphalipoproteinemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 777-783.	1.1	28
21	Risk of hospitalization for upper gastrointestinal tract bleeding. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 103-110.	2.4	27
22	Lower Plasma Klotho Concentrations Are Associated with Vascular Dementia but Not Late-Onset Alzheimer's Disease. <i>Gerontology</i> , 2018, 64, 414-421.	1.4	27
23	Paraoxonase-1 activities in individuals with different HDL circulating levels: Implication in reverse cholesterol transport and early vascular damage. <i>Atherosclerosis</i> , 2019, 285, 64-70.	0.4	27
24	Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. <i>Atherosclerosis</i> , 2009, 204, 202-207.	0.4	26
25	Determinants and clinical significance of plasma oxidized LDLs in older individuals. A 9 years follow-up study. <i>Atherosclerosis</i> , 2013, 226, 201-207.	0.4	25
26	Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: A randomized, placebo-controlled clinical trial. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 1463-1470.	1.5	24
27	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 832-841.	0.8	23
28	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. <i>Journal of Internal Medicine</i> , 2021, 290, 116-128.	2.7	21
29	Telomere length is independently associated with subclinical atherosclerosis in subjects with type 2 diabetes: a cross-sectional study. <i>Acta Diabetologica</i> , 2016, 53, 661-667.	1.2	18
30	Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-10.	1.9	17
31	Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. <i>Transfusion and Apheresis Science</i> , 2018, 57, 661-664.	0.5	17
32	Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 36-44.	1.1	16
33	Endothelial function and postprandial lipemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 121-127.	1.1	15
34	Consensus Document on substitution therapy with DHEA in the elderly. <i>Aging Clinical and Experimental Research</i> , 2006, 18, 277-300.	1.4	14
35	Combining LDL-C and HDL-C to predict survival in late life: The InChianti study. <i>PLoS ONE</i> , 2017, 12, e0185307.	1.1	14
36	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 381.	1.2	12

#	ARTICLE	IF	CITATIONS
37	Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. <i>Journal of the American Heart Association</i> , 2022, 11, e023668.	1.6	12
38	Dyslipidemia in peripheral vascular disease. <i>Current Opinion in Lipidology</i> , 1996, 7, 254-259.	1.2	9
39	Successful fenofibrate therapy for severe and persistent hypertriglyceridemia in a boy with cirrhosis and glycerol-3-phosphate dehydrogenase 1 deficiency. <i>JIMD Reports</i> , 2020, 54, 25-31.	0.7	9
40	Consensus Document on substitution therapy with testosterone in hypoandrogenic elderly men. <i>Ageing Clinical and Experimental Research</i> , 2002, 14, 439-464.	1.4	8
41	Pharmacotherapy of dyslipidemias in the adult population. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 3041-3052.	0.9	8
42	The anti-atherogenic properties of HDL particles. <i>International Congress Series</i> , 2007, 1303, 103-110.	0.2	7
43	Advanced diagnostic support in lipidology project: role for phenotypic and functional evaluation of lipoproteins in dyslipidemias. <i>Clinical Lipidology</i> , 2010, 5, 329-337.	0.4	7
44	Hypolipidemic drugs in elderly subjects: Indications and limits. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 1064-1070.	1.1	6
45	Reversible Hyperthyroidism and Cardiomyopathy Caused by Consumption of Iodocasein. <i>American Journal of the Medical Sciences</i> , 2000, 320, 148-150.	0.4	3
46	Adverse Haematological Effects of Ticlopidine. <i>Clinical Drug Investigation</i> , 2000, 19, 231-237.	1.1	3
47	Hypercholesterolemia and the ageing subject. <i>European Journal of Internal Medicine</i> , 2010, 21, e19.	1.0	3
48	Dyslipidemias in the older subject: features,significance and treatment dilemmas. <i>Clinical Lipidology</i> , 2011, 6, 339-350.	0.4	3
49	Hormonal Replacement Therapy and Lipids. <i>Menopause</i> , 1995, 2, 53.	0.8	0
50	Chronobiological Analysis of Sudden Death Observed in an Emergency Department. <i>Biological Rhythm Research</i> , 1997, 28, 404-409.	0.4	0
51	3.P.237 Is the effect of native and oxidized low density lipoproteins on nitric oxide pathway mediated through L-arginine availability?. <i>Atherosclerosis</i> , 1997, 134, 247-248.	0.4	0
52	2.P.294 Effects of soy on lipoproteins in postmenopausal women: A double blind, multicentre, placebo-controlled trial. <i>Atherosclerosis</i> , 1997, 134, 178.	0.4	0
53	Chronobiology of Symptomatic Supraventricular Paroxysmal Tachycardia. <i>Biological Rhythm Research</i> , 1998, 29, 293-299.	0.4	0
54	PO-78 An unusual case of pulmonary thromboembolism. <i>Thrombosis Research</i> , 2007, 120, S170.	0.8	0

#	ARTICLE	IF	CITATIONS
55	PO20-595 SHORT TERM EFFECT OF FOUR DIFFERENT MACRONUTRIENT ORAL LOADS ON METABOLIC PROFILE AND FLOW MEDIATED VASODILATATION IN HEALTHY YOUNG MEN. <i>Atherosclerosis Supplements</i> , 2007, 8, 162-163.	1.2	0
56	Transient massive hyperlipidaemia in a type 2 diabetic subject. <i>Internal and Emergency Medicine</i> , 2007, 2, 67-70.	1.0	0